This is a proposal to create an AIDS Clinical Research Group (CRG) at the Indiana University School of Medicine in Indianapolis. Although the number of cases of HIV infection has been relatively low in Indiana so far, it is now starting to increase, and we anticipate that during the proposed period of funding it will be more than adequate to permit us to evaluate experimental therapies for HIV infection and some of its complications. Specifically, we propose to evaluate the pharmacokinetics, toxicity, and efficacy of new anti-viral agents which have in vitro activity against HIV. Agents to be evaluated would include those provided by NIAID and synthetic oligonucleotides developed under a collaborative arrangement with Purdue University. Members of the proposed CRG have successfully established a rat pneumocystis model and an in vitro culture system for rat pneumocystis. It is now proposed to identify virulence markers including those for antibiotic resistance for different strains of pneumocystis, and to couple these with clinical evaluation of the efficacy and toxicity of agents (or combinations of agents) in the treatment of pneumocystis. In addition, antigen detection methods would be employed for diagnosis of disseminated histoplasmosis in order to better define its prevalence in patients with AIDS and to evaluate efficacy and toxicity of available, or newly developed, anti-fungal regimens. We also propose to prospectively follow a series of immune markers in order to identify those which may be predictive of progression of immunological deficit and/or disease, and to define optimum points for potential intervention with anti- viral chemotherapy. In conjunction with these studies there will be an evaluation of the cost-effectiveness of close medical follow-up of individuals with asymptomatic HIV infection and of home health versus hospital based care. In addition, we propose to expand and further evaluate a program which is designed to reduce the risk of transmission of HIV infection by providing photo identification cards which contain information on an individual's HIV antibody status. The formation of this group would focus the attention of a number of skilled investigators at Indiana University on the problem of HIV infections and would permit infected individuals in this region of the country to participate in the evaluation of new therapeutic modalities.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI025859-04
Application #
3546819
Study Section
Special Emphasis Panel (SRC (05))
Project Start
1987-09-30
Project End
1992-08-31
Budget Start
1990-09-01
Budget End
1991-08-31
Support Year
4
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Indiana University-Purdue University at Indianapolis
Department
Type
Schools of Medicine
DUNS #
005436803
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187
Venuto, Charles S; Lim, Jihoon; Messing, Susan et al. (2018) Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s. Antivir Ther 23:345-351
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459
Gupta, Samir K; Yeh, Eunice; Kitch, Douglas W et al. (2017) Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s. J Antimicrob Chemother 72:2042-2048
Verma, Anurag; Bradford, Yuki; Verma, Shefali S et al. (2017) Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 27:101-111
Bednasz, Cindy J; Venuto, Charles S; Ma, Qing et al. (2017) Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants. Ther Drug Monit 39:596-603
Verma, Shefali S; Frase, Alex T; Verma, Anurag et al. (2016) PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG). Pac Symp Biocomput 21:57-68
Moore, Carrie B; Verma, Anurag; Pendergrass, Sarah et al. (2015) Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols. Open Forum Infect Dis 2:ofu113
Lehmann, David S; Ribaudo, Heather J; Daar, Eric S et al. (2015) Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols. Pharmacogenet Genomics 25:51-9

Showing the most recent 10 out of 181 publications